---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-039300"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:45:35.439559+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MangoRx launches oral Tirzepatide weight loss tablet 'TRIM' at $399/month

## Summary
- TRIM is a compounded oral dissolvable Tirzepatide tablet priced at $399 per month.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist; clinical trials showed up to 20% weight loss in 72 weeks.
- TRIM complements existing oral Semaglutide product (SLIM), offering two GLP-1 options.
- Global GLP-1 market projected to grow from $49.3B (2024) to $157.5B by 2035 per Roots Analysis.
- Available by prescription via MangoRx telemedicine platform; targets non-injectable weight loss demand.

## SEC filing metadata
- accession: 0001493152-24-039300
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315224039300/0001493152-24-039300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315224039300/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-039300
- JSON: https://secwatch.observer/filing/0001493152-24-039300.json
- Plain text: https://secwatch.observer/filing/0001493152-24-039300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.